Literature DB >> 3612644

Anticardiolipin and complement activation: relation to clinical symptoms.

R Norberg, O Nived, G Sturfelt, M Unander, L Arfors.   

Abstract

Anticardiolipin antibodies which seldom occur in healthy persons are frequently found in systemic lupus erythematosus (SLE). Their presence, especially at high levels (greater than 10 units) are often accompanied by thromboembolic manifestations as well as thrombocytopenia and recurrent abortions. The incidence of cardiolipin antibodies was as great in SLE as in women with clinically unexplained recurrent abortions. The anticardiolipin levels remained unchanged in most patients for long periods and were remarkably unaffected by disease activity and therapy. On the other hand, in several cases the activated partial thromboplastin time which was prolonged in most patients with persistently high cardiolipin antibody levels, approached normal during treatment with prednisolone and salicylic acid. This seemed to facilitate a successful outcome of pregnancy. Absorption of sera with cardiolipin and other negatively charged phospholipids but not with uncharged phospholipids abolished the anticardiolipin activity in enzyme linked immunosorbent assay. In most sera with cardiolipin antibody levels greater than 10 units complement activation by the classical pathway could be demonstrated. Whether the anticardiolipin antibodies contributed to complement activation could not be determined.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3612644

Source DB:  PubMed          Journal:  J Rheumatol Suppl        ISSN: 0380-0903


  4 in total

1.  Complement activation by anticardiolipin antibodies.

Authors:  M B Santiago; N Gaburo; R M de Oliveira; W Cossermelli
Journal:  Ann Rheum Dis       Date:  1991-04       Impact factor: 19.103

2.  Anaemia in systemic lupus erythematosus: aetiological profile and the role of erythropoietin.

Authors:  M Voulgarelis; S I Kokori; J P Ioannidis; A G Tzioufas; D Kyriaki; H M Moutsopoulos
Journal:  Ann Rheum Dis       Date:  2000-03       Impact factor: 19.103

3.  Reactivity patterns of anti-phospholipid antibodies in systemic lupus erythematosus sera in relation to erythrocyte binding and complement activation.

Authors:  J Arvieux; B Roussel; D Ponard; M G Colomb
Journal:  Clin Exp Immunol       Date:  1991-06       Impact factor: 4.330

4.  Pathogenic Role of Complement in Antiphospholipid Syndrome and Therapeutic Implications.

Authors:  Francesco Tedesco; Maria Orietta Borghi; Maria Gerosa; Cecilia Beatrice Chighizola; Paolo Macor; Paola Adele Lonati; Alessandro Gulino; Beatrice Belmonte; Pier Luigi Meroni
Journal:  Front Immunol       Date:  2018-06-19       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.